Market Research Report

Global Noninvasive Prenatal Testing Market Report By Gestation Period (0-12 Weeks, 13-24 Weeks, 25-36 Weeks), By Risk Type (High & Average Risk, Low Risk), By Method (Ultrasound Detection, Biochemical Screening Tests, Cell-Free DNA in Maternal Plasma Tests), By Technology (NGS, Array Technology, PCR, Other Technologies), By Product (Consumables & Reagents, Instruments), By End-User (Hospitals & Clinics, Diagnostic Laboratories) And By Regions - Industry Trends, Size, Share, Growth, Estimation and Forecast, 2021-2028

ID:VMR11214554
April 2021
Report Formats: Electronic (PDF), MS EXCEL
Global Noninvasive Prenatal Testing Market Overview
The key driver impacting the noninvasive prenatal testing market is the rising incidence of gene-related disorders and chromosomal abnormalities. For instance, As per NCBI, Sickle cell disease (SCD) is one of the most common genetic hematological diseases. It accounts for 305000 births in 2010, with millions of people affected globally in 2018. As per the Center for Disease Control and Prevention (CDC), Sickle Cell Disease has an effect on over 100,000 Americans. Around one in all 365 African-American babies is born with Sickle Cell Disease in the U.S., whereas one in every 16,300 Hispanic-American babies is diagnosed with sickle cell disease. The other most widespread genetic disorder is Cystic Fibrosis.  As to the Cystic Fibrosis Foundation, More than 30,000 people living with cystic fibrosis in the United States, more than 70,000 globally, and approximately 1,000 new CF cases are diagnosed each year. Moreover, high risk of chromosomal abnormalities with rising maternal age and growing preference for noninvasive methods over invasive methods, contributing to market growth.
According to Value Market Research, the global noninvasive prenatal testing market size was valued at around USD 2750 million in 2020 and is estimated to grow at a CAGR of about 10.9% during the forecast period 2021 to 2027.

The improving reimbursement policies for average and low-risk pregnancies are estimated to augment noninvasive prenatal testing demand in the forecast period. For instance, Natera declared extended coverage from the U.S. largest Health Plan Aetna, meant for its non-invasive prenatal testing (NIPT) for all pregnancies. This coverage was the outcome of the guidelines on aneuploidy screening options published by the Society for Maternal-Fetal Medicine (SMFM) in partnership with the American College of Obstetricians and Gynecologists (ACOG). The growing technological advancement in the existing tests in terms of improved chemistry, advanced functions, detection of monogenic diseases, and bioinformatics analysis. For instance, in April 2019, Progenity, Inc. launched the Resura prenatal test for the monogenic disease through sequencing-based noninvasive cell-free DNA technology to improve its portfolio than competitive tests available in the market. However, the high costs of noninvasive prenatal testing may hamper the global noninvasive prenatal testing market in the long run. Also, the unfavorable government regulations and reliability issues-particularly in obese women, negatively impact the market. The current industry trends, such as the increased maternal age, growing product usage in new applications, and technological advancement in the field of genetic and chromosomal disorder analysis, are expected to provide market players with new market opportunities.

The noninvasive prenatal testing market is vast, with many local and global players. The noninvasive prenatal testing market is extensive, with many local and international players. The key leaders follow numerous strategies to increase their market position, such as extending product portfolio, contracts, amalgamation, expanding product portfolio, product advancement, and acquisitions to improve their market share across the globe. The known players studied in the report are Genesis Genetics (CooperSurgical, Inc.), Centogene N.V., Eurofins LifeCodexx GmbH, F. Hoffmann-La Roche Ltd (Ariosa Diagnostics), Progenity, Inc., Laboratory Corp. of America Holdings, Natera, Inc., Illumina, Inc. (Verinata Health, Inc.), MedGenome Labs Ltd., Myriad Women’s Health, Inc. (Myriad Genetics Inc/Counsyl, Inc.), QiagenQuest Diagnostics, Inc.

Global Noninvasive Prenatal Testing Market Share

In this research report, the noninvasive prenatal testing market is segmented by gestation period, risk type, method, technology, product, end-user, and region.

Analysis by Gestation period:
By gestation period, the report is segmented into 0-12 Weeks, 13-24 Weeks, 25-36 Weeks. The 13-24 Weeks dominate the gestation period segment with a 45% share in 2020. It is due to maximum noninvasive prenatal diagnosis is carried out in the second trimester of the pregnancy, and analysis of cffDNA in a sample of maternal blood collected in the first trimester develop a more accurate and reliable NIPT. Moreover, these tests also cover major complementary tests, such as ultrasound and serum screening for alpha-fetoproteins creates more testing in a 13-24 Weeks gestation period.

Analysis by Risk Type:
By risk type, the report is segmented into high & average risk and low risk. The high & average risk dominate the risk type segment with a 90% share in 2020. It is due to the increased adoption of these tests in high-risk cases in patients aged 35 years and above. Moreover, the presence of favorable payer reimbursement in this segment with growing awareness regarding prevention of chromosomal anomalies, such as Down syndrome, contributes to high & average risk segment growth in the forecast period.

Analysis by the Method:
By the method, the report is categorized into ultrasound detection, biochemical screening tests, and cell-free DNA in maternal plasma tests. The cell-free DNA-based NIPT method segment dominates the application segment with a 42.5% share in 2020. It is because cell-free DNA-based NIPT progressively more employed in foreseeing the risk of genetic conditions in prenatal care through diverse genetic analyses. Moreover, numerous research studies are being done to advance the usage of tests presented through this segment, thus contributing to the cell-free DNA-based NIPT method segment's growth in the forecast period. 

Analysis by Technology:
By technology, the report is categorized into NGS, array technology, PCR, and other technologies. The NGS technology segment dominates the technology segment with a 57% share in 2020. It is due to the extensive use of NGS technology, such as targeted genome sequencing, whole-genome sequencing, and whole-exome sequencing, for prenatal cfDNA testing. Moreover, the NGS technology leads in various aspects such as availability, efficiency, penetration, and technology, thus contributing to the NGS technology segment's growth in the forecast period.

Analysis by Product:
By product, the report is segmented into reagents & consumables, and instruments. The reagents & consumables dominate the product segment with a 76% share in 2020. It is due to the high adoption of NGS-based prenatal test that needs several reagents and assays to run sequencing process and existence of a significant number of suppliers that provides advanced solutions to isolate cell-free DNA. Moreover, easy to use than conventional methods create more demands for consumables and reagents segments in the coming years.

Analysis by End-User:
By end-use, the report is categorized into diagnostic laboratories, hospitals & clinics. The Diagnostic laboratories segment dominates the end-user segment with a 59% share in 2020. It is because of well-drafted laboratory standards for NIPT in developed regions and the high volume of NIPT tests conducted in diagnostic laboratories. Moreover, the growing trend of outsourcing testing services to diagnostic laboratories as labs operates in agreement with quality-assurance regulations to safeguard the test reproducibility and quality thus, contribute to the diagnostic laboratories segment's growth in the forecast period.

Analysis by Region:
In the regional outlook of the global non invasive prenatal testing market, the North America region dominates with the most significant market share of 45% during the forecast period. It is due to the recent addition of NIPT in coverage plans of major insurance companies and the growing volume of chromosome abnormality cases leading to various genetic disorders. Also, the launch of new products by key players and a surge in healthcare infrastructure enhancement in the United States generates more revenue. Moreover, the growing awareness of NIPT with the high preference of couples for noninvasive prenatal testing tests during IVF and other artificial insemination procedures contributes to the market's growth across North America.
 
Market Segmentation covered in the Report:
By Gestation Period
  • 0-12 Weeks
  • 13-24 Weeks
  • 25-36 Weeks
 By Risk Type 
  • High & Average Risk
  • Low Risk
By Method
  • Ultrasound Detection
  • Biochemical Screening Tests
  • Cell-Free DNA in Maternal Plasma Tests
By Technology
  • NGS
  • Array Technology
  • PCR
  • Other Technologies
By Product
  • Consumables & Reagents
  • Instruments
By End-User
  • Hospitals & Clinics
  • Diagnostic Laboratories
By Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
 METHODOLOGY

This market research report has been produced by gathering information on the basis of primary and secondary research. Secondary research has been done by using various sources which include (but not limited to) Company Websites, Paid Data Sources, Technical Journals, Financial Reports, SEC Filings, and other different industry publications. 

If specific information is required which is not currently within the scope of the report, it can be provided as a part of customization.  

1 . PREFACE
       1.1. Report Description
           1.1.1. Objective
           1.1.2. Target Audience
           1.1.3. Unique Selling Proposition (USP) & offerings
       1.2. Research Scope
       1.3. Research Methodology
           1.3.1. Market Research Process
           1.3.2. Market Research Methodology
 
2 . EXECUTIVE SUMMARY
       2.1. Highlights of Market
       2.2. Global Market Snapshot
 
3 . NONINVASIVE PRENATAL TESTING – INDUSTRY ANALYSIS
       3.1. Introduction - Market Dynamics
       3.2. Market Drivers
       3.3. Market Restraints
       3.4. Opportunities
       3.5. Industry Trends
       3.6. Porter’s Five Force Analysis
       3.7. Market Attractiveness Analysis
           3.7.1 By Gestation Period
           3.7.2 By Risk Type
           3.7.3 By Method
           3.7.4 By Technology
           3.7.5 By Product
           3.7.6 By End-User
           3.7.7 By Region
 
4 . VALUE CHAIN ANALYSIS
       4.1. Value Chain Analysis
       4.2. Raw Material Analysis
           4.2.1. List of Raw Materials
           4.2.2. Raw Material Manufactures List
           4.2.3. Price Trend of Key Raw Materials
       4.3. List of Potential Buyers
       4.4. Marketing Channel
           4.4.1. Direct Marketing
           4.4.2. Indirect Marketing
           4.4.3. Marketing Channel Development Trend
 
5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK
       5.1. Impact Analysis of Covid-19 Outbreak
           5.1.1. Direct Impact on Production
           5.1.2. Supply Chain and Market Disruption
           5.1.3. Financial Impact on Firms and Financial Markets
       5.2. COVID-19 Impact Analysis by Production, Import, Export and Demand
       5.3. Market: Pre V/S Post COVID-19
       5.4. Estimated Impact of the Coronavirus (COVID-19) Epidemic
       5.5. COVID-19: Micro and Macro Factor Analysis
 
6 . GLOBAL NONINVASIVE PRENATAL TESTING MARKET ANALYSIS BY GESTATION PERIOD
       6.1 Overview by Gestation Period
       6.2 Historical and Forecast Data
       6.3 Analysis by Gestation Period
       6.4 0-12 Weeks Market by Regions
       6.5 13-24 Weeks Market by Regions
       6.6 25-36 Weeks Market by Regions
 
7 . GLOBAL NONINVASIVE PRENATAL TESTING MARKET ANALYSIS BY RISK TYPE
       7.1 Overview by Risk Type
       7.2 Historical and Forecast Data
       7.3 Analysis by Risk Type
       7.4 High & Average Risk Market by Regions
       7.5 Low Risk Market by Regions
 
8 . GLOBAL NONINVASIVE PRENATAL TESTING MARKET ANALYSIS BY METHOD
       8.1 Overview by Method
       8.2 Historical and Forecast Data
       8.3 Analysis by Method
       8.4 Ultrasound Detection Market by Regions
       8.5 Biochemical Screening Tests Market by Regions
       8.6 Cell-Free DNA in Maternal Plasma Tests Market by Regions
 
9 . GLOBAL NONINVASIVE PRENATAL TESTING MARKET ANALYSIS BY TECHNOLOGY
       9.1 Overview by Technology
       9.2 Historical and Forecast Data
       9.3 Analysis by Technology
       9.4 NGS Market by Regions
       9.5 Array Technology Market by Regions
       9.6 PCR Market by Regions
       9.7 Other Technologies Market by Regions
 
10 . GLOBAL NONINVASIVE PRENATAL TESTING MARKET ANALYSIS BY PRODUCT
       10.1 Overview by Product
       10.2 Historical and Forecast Data
       10.3 Analysis by Product
       10.4 Consumables & Reagents Market by Regions
       10.5 Instruments Market by Regions
 
11 . GLOBAL NONINVASIVE PRENATAL TESTING MARKET ANALYSIS BY END-USER
       11.1 Overview by End-User
       11.2 Historical and Forecast Data
       11.3 Analysis by End-User
       11.4 Hospitals & Clinics Market by Regions
       11.5 Diagnostic Laboratories Market by Regions
 
12 . GLOBAL NONINVASIVE PRENATAL TESTING MARKET ANALYSIS BY GEOGRAPHY
       12.1. Regional Outlook
       12.2. Introduction
       12.3. North America
           12.3.1. Overview, Historic and Forecast Data
           12.3.2. North America By Segment
           12.3.3. North America By Country
           12.3.4. United State
           12.3.5. Canada
           12.3.6. Mexico
       12.4. Europe
           12.4.1. Overview, Historic and Forecast Data
           12.4.2. Europe by Segment
           12.4.3. Europe by Country
           12.4.4. United Kingdom
           12.4.5. France
           12.4.6. Germany
           12.4.7. Italy
           12.4.8. Russia
           12.4.9. Rest Of Europe
       12.5. Asia Pacific
           12.5.1. Overview, Historic and Forecast Data
           12.5.2. Asia Pacific by Segment
           12.5.3. Asia Pacific by Country
           12.5.4. China
           12.5.5. India
           12.5.6. Japan
           12.5.7. South Korea
           12.5.8. Australia
           12.5.9. Rest Of Asia Pacific
       12.6. Latin America
           12.6.1. Overview, Historic and Forecast Data
           12.6.2. Latin America by Segment
           12.6.3. Latin America by Country
           12.6.4. Brazil
           12.6.5. Argentina
           12.6.6. Peru
           12.6.7. Chile
           12.6.8. Rest of Latin America
       12.7. Middle East & Africa
           12.7.1. Overview, Historic and Forecast Data
           12.7.2. Middle East & Africa by Segment
           12.7.3. Middle East & Africa by Country
           12.7.4. Saudi Arabia
           12.7.5. UAE
           12.7.6. Israel
           12.7.7. South Africa
           12.7.8. Rest Of Middle East And Africa
 
13 . COMPETITIVE LANDSCAPE OF THE NONINVASIVE PRENATAL TESTING COMPANIES
       13.1. Noninvasive Prenatal Testing Market Competition
       13.2. Partnership/Collaboration/Agreement
       13.3. Merger And Acquisitions
       13.4. New Product Launch
       13.5. Other Developments
 
14 . COMPANY PROFILES OF NONINVASIVE PRENATAL TESTING INDUSTRY
       14.1. Company Share Analysis
       14.2. Market Concentration Rate
       14.3. Genesis Genetics (CooperSurgical, Inc.)
           14.3.1. Company Overview
           14.3.2. Financials
           14.3.3. Products
           14.3.4. Recent Developments
       14.4. Centogene N.V.
           14.4.1. Company Overview
           14.4.2. Financials
           14.4.3. Products
           14.4.4. Recent Developments
       14.5. Eurofins LifeCodexx GmbH
           14.5.1. Company Overview
           14.5.2. Financials
           14.5.3. Products
           14.5.4. Recent Developments
       14.6. F. Hoffmann-La Roche Ltd (Ariosa Diagnostics)
           14.6.1. Company Overview
           14.6.2. Financials
           14.6.3. Products
           14.6.4. Recent Developments
       14.7. Progenity, Inc.
           14.7.1. Company Overview
           14.7.2. Financials
           14.7.3. Products
           14.7.4. Recent Developments
       14.8. Laboratory Corp. of America Holdings
           14.8.1. Company Overview
           14.8.2. Financials
           14.8.3. Products
           14.8.4. Recent Developments
       14.9. Natera, Inc.
           14.9.1. Company Overview
           14.9.2. Financials
           14.9.3. Products
           14.9.4. Recent Developments
       14.10. Illumina, Inc.
           14.10.1. Company Overview
           14.10.2. Financials
           14.10.3. Products
           14.10.4. Recent Developments
       14.11. (Verinata Health, Inc.)
           14.11.1. Company Overview
           14.11.2. Financials
           14.11.3. Products
           14.11.4. Recent Developments
       14.12. MedGenome Labs Ltd.
           14.12.1. Company Overview
           14.12.2. Financials
           14.12.3. Products
           14.12.4. Recent Developments
       14.13. Myriad Women’s Health, Inc.
           14.13.1. Company Overview
           14.13.2. Financials
           14.13.3. Products
           14.13.4. Recent Developments
       14.14. (Myriad Genetics Inc/Counsyl, Inc.)
           14.14.1. Company Overview
           14.14.2. Financials
           14.14.3. Products
           14.14.4. Recent Developments
       14.15. QiagenQuest Diagnostics, Inc.
           14.15.1. Company Overview
           14.15.2. Financials
           14.15.3. Products
           14.15.4. Recent Developments
 
 *Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies
 
 LIST OF TABLES
 

  •  Market Snapshot
  •  Drivers : Impact Analysis
  •  Restraints : Impact Analysis
  •  List of Raw Material
  •  List of Raw Material Manufactures
  •  List of Potential Buyers
  •  COVID-19 Impact Analysis by Production, Import, Export and Demand
  •  Pre V/S Post COVID-19
  •  Estimated Impact Of The Coronavirus (Covid-19) Epidemic
  •  COVID-19: Micro and Macro Factor Analysis
  •  Analysis by Gestation Period (USD MN)
  •  0-12 Weeks Market by Geography (USD MN)
  •  13-24 Weeks Market by Geography (USD MN)
  •  25-36 Weeks Market by Geography (USD MN)
  •  Analysis Market by Risk Type  (USD MN)
  •  High & Average Risk Market by Geography (USD MN)
  •  Low Risk Market by Geography (USD MN)
  •  Analysis by Method (USD MN)
  •  Ultrasound Detection Market by Geography (USD MN)
  •  Biochemical Screening Tests Market by Geography (USD MN)
  •  Cell-Free DNA in Maternal Plasma Tests Market by Geography (USD MN)
  •  Analysis by Technology (USD MN)
  •  NGS Market by Geography (USD MN)
  •  Array Technology Market by Geography (USD MN)
  •  PCR Market by Geography (USD MN)
  •  Other Technologies Market by Geography (USD MN)
  •  Analysis by Product (USD MN)
  •  Consumables & Reagents Market by Geography (USD MN)
  •  Instruments Market by Geography (USD MN)
  •  Analysis by End-User (USD MN)
  •  Hospitals & Clinics Market by Geography (USD MN)
  •  Diagnostic Laboratories Market by Geography (USD MN)
  •  Global Noninvasive Prenatal Testing Market by Geography (USD MN)
  •  North America Market Analysis (USD MN)
  •  United State Market Analysis (USD MN)
  •  Canada Market Analysis (USD MN)
  •  Mexico Market Analysis (USD MN)
  •  Europe Market Analysis (USD MN)
  •  Europe Market Estimate by Country (USD MN)
  •  United Kingdom Market Analysis (USD MN)
  •  France Market Analysis (USD MN)
  •  Germany Market Analysis (USD MN)
  •  Italy Market Analysis (USD MN)
  •  Russia Market Analysis (USD MN)
  •  Spain Market Analysis (USD MN)
  •  Rest of Europe Market Analysis (USD MN)
  •  Asia Pacific Market Analysis (USD MN)
  •  China Market Analysis (USD MN)
  •  Japan Market Analysis (USD MN)
  •  India Market Analysis (USD MN)
  •  South Korea Market Analysis (USD MN)
  •  Australia Market Analysis (USD MN)
  •  Rest of Asia Pacific Market Analysis (USD MN)
  •  Latin America Market Analysis (USD MN)
  •  Brazil Market Analysis (USD MN)
  •  Argentina Market Analysis (USD MN)
  •  Peru Market Analysis (USD MN)
  •  Chile Market Analysis (USD MN)
  •  Rest of Latin America Market Analysis (USD MN)
  •  Middle East & Africa Market Analysis (USD MN)
  •  Saudi Arabia Market Analysis (USD MN)
  •  UAE Market Analysis (USD MN)
  •  Israel Market Analysis (USD MN)
  •  South Africa Market Analysis (USD MN)
  •  Rest of Middle East and Africa Market Analysis (USD MN)
  •  Partnership/Collaboration/Agreement
  •  Mergers And Acquisiton
 
 LIST OF FIGURES
 
  •  Research Scope of Noninvasive Prenatal Testing Report
  •  Market Research Process
  •  Market Research Methodology
  •  Global Noninvasive Prenatal Testing Market Size, by Region (USD MN)
  •  Porters Five Forces Analysis
  •  Market Attractiveness Analysis by Gestation Period
  •  Market Attractiveness Analysis by Risk Type
  •  Market Attractiveness Analysis by Method
  •  Market Attractiveness Analysis by Technology
  •  Market Attractiveness Analysis by Product
  •  Market Attractiveness Analysis by End-User
  •  Market Attractiveness Analysis by Region
  •  Value Chain Analysis
  •  Global Market Analysis by Gestation Period (USD MN)
  •  0-12 Weeks Market by Geography (USD MN)
  •  13-24 Weeks Market by Geography (USD MN)
  •  25-36 Weeks Market by Geography (USD MN)
  •  Global Market Analysis by Risk Type  (USD MN)
  •  High & Average Risk Market by Geography (USD MN)
  •  Low Risk Market by Geography (USD MN)
  •  Global Market Analysis by Method (USD MN)
  •  Ultrasound Detection Market by Geography (USD MN)
  •  Biochemical Screening Tests Market by Geography (USD MN)
  •  Cell-Free DNA in Maternal Plasma Tests Market by Geography (USD MN)
  •  Global Market Analysis by Technology (USD MN)
  •  NGS Market by Geography (USD MN)
  •  Array Technology Market by Geography (USD MN)
  •  PCR Market by Geography (USD MN)
  •  Other Technologies Market by Geography (USD MN)
  •  Global Market Analysis by Product (USD MN)
  •  Consumables & Reagents Market by Geography (USD MN)
  •  Instruments Market by Geography (USD MN)
  •  Global Market Analysis by End-User (USD MN)
  •  Hospitals & Clinics Market by Geography (USD MN)
  •  Diagnostic Laboratories Market by Geography (USD MN)
  •  Global Market by Revenue
  •  North America Market by Revenue
  •  Europe Market by Revenue
  •  Asia Pacific Market by Revenue
  •  Latin America Market by Revenue
  •  Middle East & Africa Market by Revenue
  •  Recent Development in Industry
  •  Company Market Share Analysis
 
 * Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Objectives of Study

  • Define and measure the global market
  • Volume or revenue forecast of the global market and its various sub-segments with respect to main geographies
  • Analyze and identify major market trends along with the factors driving or inhibiting the market growth
  • Study the company profiles of the major market players with their market share
  • Analyze competitive developments

Why Choose Us

Client First Policy
Excellent Quality
After Sales Support
24/7 Email Support

Clients

Testimonials